Pirfenidone
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pirfenidone |
| DrugBank ID | DB04951 |
| Brand Names (EU) | Esbriet, Pirfenidone axunio (previously Pirfenidone AET) |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.71% |
Approved Indication (EMA)
Pirfenidone AET is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | extracutaneous mastocytoma | 99.71% | DL |
| 2 | dermatofibrosarcoma protuberans | 99.41% | DL |
| 3 | aggressive systemic mastocytosis | 99.33% | DL |
| 4 | heart fibrosarcoma | 99.29% | DL |
| 5 | conventional fibrosarcoma | 99.26% | DL |
| 6 | autosomal recessive familial Mediterranean fever | 99.25% | DL |
| 7 | kidney fibrosarcoma | 99.24% | DL |
| 8 | hepatic infarction | 99.24% | DL |
| 9 | fibroblastic neoplasm | 99.23% | DL |
| 10 | low grade fibromyxoid sarcoma | 99.19% | DL |
| 11 | hepatic veno-occlusive disease | 99.04% | DL |
| 12 | peliosis hepatis | 98.88% | DL |
| 13 | Kimura disease | 98.83% | DL |
| 14 | syndrome with combined immunodeficiency | 98.79% | DL |
| 15 | X-linked lymphoproliferative syndrome | 98.77% | DL |
| 16 | leishmaniasis, diffuse cutaneous | 98.75% | DL |
| 17 | familial rhabdoid tumor | 98.73% | DL |
| 18 | Castleman disease | 98.70% | DL |
| 19 | benign PEComa | 98.67% | DL |
| 20 | lymphangiomyoma | 98.67% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.